ELPA Vice-President Julio Burman and ELPA Director Prof Gamal Shiha attended the EASL Liver Cancer Summit 2023 on April 20-22. Liver cancer is a significant health problem, and hepatocellular carcinoma (HCC) is considered one of the leading causes of cancer-related deaths worldwide. It is associated with many liver diseases such as Hepatitis B, C and D, excessive alcohol intake, NASH and NAFLD. Recent findings will likely soon transform the way we diagnose liver cancer, screen at-risk patients, and treat patients with primary liver cancer.
The Summit 2023 brought together all stakeholders engaged in tackling liver cancer, including clinicians, researchers, policy and public health specialists, nurses and allied health professionals, patient representatives, and industry professionals. The programme of the Summit addressed essential advances in the way we understand the pathogenesis of the two most common primary liver malignancies – hepatocellular and cholangiocellular carcinoma – and discuss diagnosis and treatment of patients who suffer from these primary liver tumours.